Basic study on novel antibody therapy targeting colon cancer stem cells
| Project/Area Number |
16K15614
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | Lgr5 / Syntenin-1 / LC-MS/MS解析 / 予後マーカー / 大腸癌 / 幹細胞 / 活性酸素種 / 再発大腸癌 / 癌幹細胞仮説 / スプライシング / 進行再発大腸癌 / 癌幹細胞 / 分子標的治療 |
|---|
| Outline of Final Research Achievements |
As a result of LC-MS / MS analysis, syntenin-1 was identified as a molecule conjugated to the colon cancer stem cell marker Lgr5. The relationship between clinicopathological factors and prognosis of syntenin-1 expression was examined and functional analysis was performed. Overall survival rate was low expression group: high expression group = 97.8%: 63.8% (p = 0.001), 5 year low relapse survival rate was low expression group: high expression group = 92.4%: 61.7% (p = 0.001). The rate of recurrence was significantly higher and the survival rate was lower in the high expression group of syntenin-1. Silencing Syntenin-1 increased the sensitivity to L-OHP with significant difference (p <0.05).
|
Report
(3 results)
Research Products
(7 results)
